Opiant Pharmaceuticals, Inc. (OPNT) EPS Estimated At $-1.19

December 10, 2017 - By Adrian Mccoy

 Opiant Pharmaceuticals, Inc. (OPNT) EPS Estimated At $ 1.19

Analysts expect Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) to report $-1.19 EPS on December, 15.They anticipate $0.89 EPS change or 296.67 % from last quarter’s $-0.3 EPS. After having $-0.17 EPS previously, Opiant Pharmaceuticals, Inc.’s analysts see 600.00 % EPS growth. The stock decreased 0.76% or $0.23 during the last trading session, reaching $30.01. About 24,529 shares traded. Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) has 0.00% since December 10, 2016 and is . It has underperformed by 16.70% the S&P500.

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops opioid antagonist treatments for addictions and related disorders. The company has market cap of $62.06 million. The firm offers NARCAN nasal spray, a treatment to reverse opioid overdoses. It has a 43.75 P/E ratio. It is also involved in developing treatments for binge eating disorder and cocaine use disorder, as well as Bulimia Nervosa, an eating disorder; and heroin vaccine.

More notable recent Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) news were published by: Benzinga.com which released: “A Look At Opiant Pharmaceuticals, The Stock That Skyrocketed On Trump’s Opioid …” on October 26, 2017, also Globenewswire.com with their article: “Opiant Pharmaceuticals, Inc. Announces Phase I Data for OPNT002 in Development …” published on July 19, 2017, Globenewswire.com published: “Opiant Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2017 Financial …” on June 15, 2017. More interesting news about Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) were released by: Thestreet.com and their article: “Opiant Pharmaceuticals Looks to Create a Heroin Vaccine and Treat Addictions” published on July 28, 2017 as well as Globenewswire.com‘s news article titled: “Opiant Pharmaceuticals, Inc. Announces NARCANĀ® Nasal Spray Royalty Monetization” with publication date: December 15, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.